Recent Updates
Recently added Catalysts

Processa Pharmaceuticals, Inc.

PCSAFDA catalysts, PDUFA dates & pipeline intelligence
$1.73
▲ +0.01 · +0.58%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full PCSA financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.0452W HIGH $8.88
Volume
21.67 K
Value Traded
37.32 K
Short % Float
1.1%
Days to Cover
1.0
-7.49%Week
0%1 Month
-19.53%3 Month
-33.72%6 Month
-99.92%5 Year
-99.99%All Time

Cash Data

Unlock PCSA cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
4.84 M
EPS (TTM)
-69.03
P/E Ratio
-
Ent. Value
-175.36 M
Total Shares
2.80 M
Float Shares
2.38 M
Insiders
14.79%
Institutions
12.81%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 2 data readout
VT7208
IgE-mediated peanut allergy
Phase 2-Unknown
Unlock every PCSA catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

PCSA Catalyst Timeline

Dated clinical, regulatory and corporate events for Processa Pharmaceuticals, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Processa Pharmaceuticals, Inc.

337Total events
7Upcoming
68Tier-1 (high impact)
2013 to 2029Coverage

Upcoming catalysts 2

T2Trial Initiation
Subscribe to view catalyst details
VT7208
T1Topline Readout
Subscribe to view catalyst details
VT7208

Event history 50

●Management ChangeCorporate
Gregory J. Flesher appointed Chief Operating Officer
▲IND ClearanceVT7208IND
FDA clears IND for Phase 2 study of VT-7208 in CSU
chronic spontaneous urticariasource ↗
▲Partnership / LicenseCorporate
Research collaboration and exclusive option agreement with Generian Pharmaceuticals for oral macrocyclic peptide FcRn antagonist program
●Management ChangeCorporate
Sheila Gujrathi, M.D. appointed Executive Chair of Processa Board
▼Equity OfferingCorporate
Concurrent private placement financing of approximately $200 million
▲AcquiredCorporate
Processa acquires Vidya Therapeutics
◆Oral PresentationPresentation
Investor webcast on July 29, 2026 at 8:30 a.m. ET
▲AcquiredCorporate
Processa acquired Vidya Therapeutics in sign-and-close reverse merger
▼Equity OfferingCorporate
Concurrent private placement financing of approximately $200 million
▼Equity OfferingCorporate
~$200 million private placement accompanying Vidya acquisition
Unlock the full PCSA catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How PCSA actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-03-31PCS6422+Cap (NGC-Cap) Phase 2 data readout Phase 2
Unlock 11 more PCSA historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
5
Drugs Scored
rNPV / MCap
Top Drug
Top 30%
Micro Cap
(rank 218 of 725)
Percentile Rank
Showing 6 of 6 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
VT7208 Small MoleculesNCT07085507Multiple SclerosisPhase 1/2 RECRUITING 100Dec 31, 2027
RX-3117 Small MoleculesCompletedNCT03189914Metastatic Pancreatic CancerPhase 1/2 COMPLETED 46Nov 21, 2019
RX-3117 Small MoleculesCompletedNCT02030067Solid TumorPhase 1/2 COMPLETED 127Dec 1, 2019
PCS6422 Small MoleculesCompletedNCT04861987Advanced CancerPhase 1 COMPLETED 23Sep 9, 2024
PCS12852 Small MoleculesCompletedNCT05270460GastroparesisPhase 2 COMPLETED 25Oct 6, 2022
PCS499 Small MoleculesCompletedNCT03698864Necrobiosis LipoidicaPhase 2 COMPLETED 12Feb 25, 2020
Unlock the PCSA pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every PCSA program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
NGC-Cap advanced or metastatic breast cancerPhase 22026-01-13increases exposure to capecitabine’s cancer-killing metabolites; maintaining a safety profile comparable to standard capecitabine monotherapyRead MoreProcessa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare ConferenceRead More
Scroll for more · summaries link to the source press release
Unlock every PCSA trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock PCSA insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Ng George KDirector, Officer (Chief Executive Officer)Option 1,600 17,092 held$0.00 08/08/2026
Unlock the full PCSA insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
SOLEUS CAPITAL MANAGEMENT, L.P. 0 % 263.95 K 160.94 K
Unlock every fund holding PCSA
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in PCSA
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see PCSA ownership
Insider and institutional ownership, quarter by quarter.

PCSA Short Interest

Shares sold short, counted twice a month.

1.1%
Short % of Float
of tradable shares sold short
26.1K
Shares Sold Short
-43.8% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
27.7K
Avg Daily Volume
the average used for days to cover
Unlock PCSA short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock PCSA option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live PCSA option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock PCSA options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How PCSA ranks across every disease it competes in

Competitive Position is a premium feature
See how PCSA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

PCSA News

PCSA
Nov 5, 2026
PCSAConferences/Events

Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

Processa Pharmaceuticals announced that Executive Chair Sheila Gujrathi will speak at the UBS Global Healthcare Conference and the Evercore ISI HealthCONx Conference. The company also noted that management will host one-on-one investor meetings during these events. These conferences follow the July 2026 acquisition of Vidya Therapeutics for approximately $200 million. Processa now focuses on its lead program VT-7208 for immune-mediated diseases.

Read more →
PCSA
Nov 4, 2026
PCSAGeneral

Processa Pharmaceuticals Announces Key Leadership Appointments

Processa Pharmaceuticals announced key leadership appointments to support its growth. Gregory J. Flesher becomes COO, while Craig Coburn, Ashley Hall, and Michael P. Cruse take on executive roles. The company is advancing VT-7208, a Bruton’s tyrosine kinase inhibitor, with FDA clearance for its Phase 2 study in chronic spontaneous urticaria.

Read more →
PCSA
Oct 29, 2026
PCSAPhases

Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics

Processa Pharmaceuticals announced significant progress following its acquisition of Vidya Therapeutics. The FDA has cleared the IND for a Phase 2 study of VT-7208 in chronic spontaneous urticaria, with additional studies planned. The company also expanded its pipeline through a collaboration with Generian Pharmaceuticals and appointed Dr. Sheila Gujrathi as Executive Chair.

Read more →
PCSA
Jul 29, 2026
PCSAGeneral
▼ -33.4%on this news

PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS

Processa Pharmaceuticals has announced the acquisition of Vidya Therapeutics, which includes the promising BTK inhibitor VT-7208. This acquisition is complemented by a $200 million private placement financing aimed at advancing VT-7208 through key clinical milestones in food allergy, chronic spontaneous urticaria, and relapsing multiple sclerosis. The funding is expected to sustain operations until the second half of 2029.

Read more →
PCSA
Jan 13, 2026
PCSAConferences/Events

Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference

Processa Pharmaceuticals will attend the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026. CEO George Ng and Chief Business Officer Patrick Lin will hold one-on-one meetings to discuss their clinical pipeline, particularly the Phase 2 study of NGC-Cap for advanced breast cancer. Preliminary data indicate that NGC-Cap enhances exposure to effective metabolites while maintaining safety.

Read more →
PCSA
Jan 5, 2026
PCSAPhases
▲ +10.2%on this news

Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study

Processa Pharmaceuticals has completed the enrollment of 20 patients for a formal interim analysis in its Phase 2 study of NGC-Cap, a combination treatment for advanced breast cancer. This analysis aims to compare the safety and efficacy of NGC-Cap against standard capecitabine therapy. Results are anticipated in the first quarter of 2026, which will guide future study design and dose optimization.

Read more →
PCSA
Dec 18, 2025
PCSAPhases
▼ -41.6%on this news

Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer

Processa Pharmaceuticals provided an update on its Phase 2 study of NGC-Cap, a combination of PCS6422 and capecitabine for metastatic breast cancer. Preliminary data from 16 of 19 patients indicate that NGC-Cap enhances exposure to effective cancer-killing metabolites while maintaining a comparable safety profile to standard capecitabine therapy. The full interim analysis is expected in early 2026.

Read more →
PCSA
Nov 5, 2025
PCSAPhases

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

Processa Pharmaceuticals announced that its abstract for the adaptive Phase 2/3 study of PCS499 in patients with FSGS has been accepted for presentation at ASN Kidney Week 2025. The study aims to optimize dosing and address the urgent need for effective therapies in this rare kidney disease. PCS499 has demonstrated a favorable safety profile, potentially allowing for greater therapeutic benefits compared to existing treatments.

Read more →
PCSA
Aug 7, 2025
PCSAGeneral

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

Processa Pharmaceuticals has announced a strategic investment and is exploring cryptocurrency treasury strategies to enhance financial flexibility and support its clinical development programs. The company aims to diversify its capital base while maintaining compliance with regulatory standards. CEO George Ng emphasized the commitment to delivering meaningful therapies for cancer patients and optimizing outcomes for shareholders.

Read more →
PCSA
Jul 1, 2025
PCSAGeneral

Processa Pharmaceuticals Provides Portfolio and Business Update

Processa Pharmaceuticals secured a binding term sheet with Intact Therapeutics for an exclusive option to license PCS12852. The deal offers up to $454 million in milestone payments and a 12% royalty on future sales. The company also raised $7 million through a capital infusion to strengthen its balance sheet. Processa continues enrolling patients in its Phase 2 study of PCS6422 for metastatic breast cancer.

Read more →
PCSA
Jun 17, 2025
PCSAGeneral
▼ -42.2%on this news

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

Processa Pharmaceuticals announced the pricing of a public offering of 28 million shares at $0.25 each, aiming to raise $7 million. The proceeds will be used to continue the Phase 2 clinical trial for NCG-Cap and for general corporate purposes. The offering is expected to close around June 18, 2025.

Read more →
PCSA
Jun 17, 2025
PCSAGeneral
▲ +15.5%on this newsshared move

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

Processa Pharmaceuticals has signed a binding term sheet with Intact Therapeutics, granting them the exclusive option to license PCS12852, a promising treatment for gastroparesis. The agreement includes a $2.5 million option fee and potential milestone payments exceeding $452 million. PCS12852 has shown strong safety and efficacy in clinical trials, positioning it as a leading candidate for gastrointestinal motility disorders.

Read more →
PCSA
Jun 13, 2025
PCSAConferences/Events
▼ -24.9%on this newsshared move

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

Processa Pharmaceuticals will participate in the 2025 BIO International Convention in Boston, where its leadership will meet with potential partners and investors. The focus will be on the company's Next Generation Cancer therapies, particularly NGC-Cap, which is currently in a Phase 2 trial for metastatic breast cancer. This event provides an opportunity to showcase their clinical advancements and regulatory science approach.

Read more →
PCSA
May 30, 2025
PCSAConferences/Events

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

Processa Pharmaceuticals announced that three abstracts regarding its cancer drug pipeline were accepted for the 2025 ASCO Annual Meeting. The presentations cover preclinical data for PCS11T and clinical results for PCS6422 in breast cancer. The company highlighted a Phase 1b study that defined the maximum tolerated dose and recommended phase 2 dose range for the combination therapy. These updates reflect ongoing progress in its next generation cancer programs.

Read more →
PCSA
Apr 15, 2025
PCSAConferences/Events

Processa Pharmaceuticals’ Dr. David Young to Present at World Orphan Drug Congress USA 2025

Processa Pharmaceuticals announced that Dr. David Young will present at the World Orphan Drug Congress USA 2025. His presentation will focus on applying FDA's Project Optimus principles to enhance drug efficacy and safety for rare diseases. This aligns with Processa's mission to develop next-generation cancer therapies.

Read more →
PCSA
Mar 18, 2025
PCSAConferences/Events
▼ -5.1%on this news

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Processa Pharmaceuticals will present at the MedInvest Biotech and Pharma Investor Conference on March 28, 2025. The company aims to showcase its innovative cancer therapies that enhance efficacy and safety. Management will also engage in one-on-one meetings with investors during the event. The presentation will be accessible on the company's website.

Read more →
PCSA
Feb 7, 2025
PCSAConferences/Events
▲ +10.4%on this news

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Processa Pharmaceuticals will present at the 2025 BIO CEO & Investor Conference on February 11, 2025. The company aims to showcase its innovative approach to developing next-generation cancer therapies that enhance safety and efficacy. Management will also hold one-on-one meetings with investors during the event, promoting further engagement and collaboration.

Read more →
PCSA
Jan 30, 2025
PCSAGeneral
▲ +10.6%on this news

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals has successfully closed a $5 million public offering priced at-the-market under Nasdaq rules. The offering included participation from the company's CEO, board members, and institutional investors. Gross proceeds are aimed at advancing their pipeline of next-generation chemotherapeutic drugs. The registration statement for the offering was declared effective by the SEC shortly before the closing date.

Read more →
PCSA
Jan 28, 2025
PCSAGeneral

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals has announced the pricing of a $5 million public offering, which includes 8,050,672 shares of common stock and accompanying Series A and B warrants. The offering is led by the company's CEO and various board members, with institutional investor involvement. The completion of the offering is subject to customary closing conditions and is expected to close by January 29, 2025. Additionally, the company will seek stockholder approval for the issuance of shares related to the warrants within 90 days post-offering.

Read more →

About Processa Pharmaceuticals, Inc.

Vero Beach, FL 12 employees processapharmaceuticals.com
Headquarters601 21ST STREET, SUITE 300, VERO BEACH, FL, 32960
BIOPHARMAWATCH ELITE
Trade the next PCSA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime